The FDA today announced the expanded approval of Lucentis 0.3 mg for the treatment of diabetic retinopathy in patients with diabetic macular edema, according to a news release from the agency.Administered by a physician as an injection into the eye onc…
FDA approves Lucentis for diabetic retinopathy in patients with diabetic macular edema
The FDA today announced the expanded approval of Lucentis 0.3 mg for the treatment of diabetic retinopathy in patients with diabetic macular edema, according to a news release from the agency.Administered by a physician as an injection into the eye onc…
Allegro receives $2 million grant to support phase 2 study of Luminate
Allegro Ophthalmics has been awarded a $2 million grant from the Type 1 Diabetes Program of the Leona M. and Harry B. Helmsley Charitable Trust, according to a press release.The grant will support the company’s phase 2 study of Luminate (ALG-1001) for the treatment of diabetic macular edema.
Allergan reports Q4 sales increase, update on pending acquisition by Actavis
Allergan announced operating results for the quarter ended Dec. 31, with a declaration of a $0.05 per share fourth-quarter dividend, payable on March 20 to shareholders on record as of Feb. 9, according to a company press release.The company reported t…
Posterior corneal elevation, irregular astigmatism affect vision in childhood glaucoma
An increase in posterior corneal elevation and irregular astigmatism may contribute to visual disability in patients with childhood glaucoma, according to a study.The cross-sectional, observational study examined 58 eyes of patients with childhood glau…
New study shows that 25% of homeless people in Toronto have vision problems
Twenty-five per cent of homeless people surveyed in Toronto had vision problems up to and including blindness, four times higher than the rate of the overall population in North America, a new study by St. Michael’s Hospital has found.